Safety, pharmacokinetics, and preliminary efficacy of AMX-500 in metastatic castration resistant prostate cancer (mCRPC
Phase 1
Recruiting
- Conditions
- Therapeutic area: Diseases [C] - Neoplasms [C04]Hormone-refractory prostate cancerMedDRA version: 21.1Level: PTClassification code: 10062904Term: Hormone-refractory prostate cancer Class: 100000004864
- Registration Number
- CTIS2023-503495-24-00
- Lead Sponsor
- Sanofi-Aventis Recherche & Developpement
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 271
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets does AMX-500 modulate in metastatic castration-resistant prostate cancer (mCRPC)?
How does AMX-500's preliminary efficacy compare to enzalutamide or abiraterone in mCRPC patients?
Which biomarkers correlate with response to AMX-500 in hormone-refractory prostate cancer subtypes?
What are the most common adverse events reported in Sanofi's phase I AMX-500 trial for mCRPC?
Are there combination therapies involving AMX-500 and PARP inhibitors for mCRPC under investigation?